Saifullah M, Khan M, Usman MA, Mehmood Q, Mehdi AM. OraQuick hepatitis C virus self-test: A new frontier in hepatitis C screening. World J Virol 2025; 14(3): 109614 [PMID: 41025092 DOI: 10.5501/wjv.v14.i3.109614]
Corresponding Author of This Article
Abbas M Mehdi, MD, Department of Medicine, International School of Medicine, International University of Kyrgyzstan, 7 April Street, 6, Oktyabrsky District, Bishkek 720065, Kyrgyzstan. malikmehdi0508@gmail.com
Research Domain of This Article
Infectious Diseases
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Sep 25, 2025 (publication date) through Nov 11, 2025
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Virology
ISSN
2220-3249
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Saifullah M, Khan M, Usman MA, Mehmood Q, Mehdi AM. OraQuick hepatitis C virus self-test: A new frontier in hepatitis C screening. World J Virol 2025; 14(3): 109614 [PMID: 41025092 DOI: 10.5501/wjv.v14.i3.109614]
World J Virol. Sep 25, 2025; 14(3): 109614 Published online Sep 25, 2025. doi: 10.5501/wjv.v14.i3.109614
OraQuick hepatitis C virus self-test: A new frontier in hepatitis C screening
Muneeb Saifullah, Mavra Khan, Muhammad Ashhad Usman, Qasim Mehmood, Abbas M Mehdi
Muneeb Saifullah, Mavra Khan, Muhammad Ashhad Usman, Qasim Mehmood, Department of Medicine, King Edward Medical University, Lahore 54000, Punjab, Pakistan
Abbas M Mehdi, Department of Medicine, International School of Medicine, International University of Kyrgyzstan, Bishkek 720065, Kyrgyzstan
Author contributions: Saifullah M conceived the idea and revised the manuscript; Saifullah M, Khan M, Usman MA, Mehmood Q and Mehdi AM wrote and reviewed the manuscript; All authors thoroughly reviewed and approved the final version of the manuscript.
Conflict-of-interest statement: All authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Abbas M Mehdi, MD, Department of Medicine, International School of Medicine, International University of Kyrgyzstan, 7 April Street, 6, Oktyabrsky District, Bishkek 720065, Kyrgyzstan. malikmehdi0508@gmail.com
Received: May 19, 2025 Revised: June 11, 2025 Accepted: July 18, 2025 Published online: September 25, 2025 Processing time: 132 Days and 16.7 Hours
Abstract
According to the World Health Organization, an estimated 58 million people worldwide are chronically infected with hepatitis C virus (HCV), yet only about 20% have been formally diagnosed. Traditional laboratory–based antibody and RNA assays require infrastructure and trained personnel, limiting their uptake in resource-limited and hard-to-reach settings. The OraQuick HCV self-test (HCVST) is the first World Health Organization-prequalified HCVST, which delivers results in 20-40 min via an easy-to-use gum-swab format. Field evaluations report a sensitivity of about 97%–98% and a specificity of about 99%–100% that are comparable with those of blood-based lateral-flow assays (e.g., Alere Truline, SD Bioline). Usability studies demonstrated an acceptability rate of over 90% and a correct self-test completion rate of over 85% in key populations. HCVST with the OraQuick HCVST kit provides a practical, evidence-based approach to closing diagnostic gaps, particularly among underserved or stigmatized populations. To maximize the public health impact, programs should integrate self-testing into national screening algorithms, ensure linkage to RNA confirmation and treatment, and consider economic and operational contexts.
Core Tip: The OraQuick hepatitis C virus self-test, designed for home use, offers a profound yet straightforward solution for early detection, empowering individuals to take charge of their health and bringing us closer to the goal of hepatitis C virus eradication.
